Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 January 2019 | Story Charlene Stanley | Photo Charlene Stanley
Michele Middle
Michelle Middle, CMO of Farmovs, looks forward to expanding their operations after the UFS acquired 100% shareholding in 2018.

In medical research, there are NO shortcuts.

The journey of a new medicine from lab to pharmacy shelf takes on average at least 10 years.

Michelle Middle’s journey from young medical graduate starting her first job at FARMOVS to becoming the company’s Chief Medical Officer, was more than twice that long. It was a journey that systematically and adequately equipped her to now Co-captain this flagship enterprise through its biggest challenge yet.

Michelle remembers how Farmovs started in 1974 as a research centre in the Department of Pharmacology. After graduating as medical doctor, she joined Farmovs in 1993, shortly before they moved to their current extensive facilities just south of the Sasol Library.

In 2000, international Clinical Research Organization (CRO) giant Parexel acquired a 70% shareholding, and the name changed to Farmovs-Parexel.

“Parexel really invested a lot in infrastructure and technology, bringing facilities here on par with the best in the world,” says Michelle.

Her own journey in medical research took her to George and later to the US and UK, where she held various international executive leadership positions in international companies.

When the UFS acquired a 100% shareholding in Farmovs earlier this year, she came full circle, as she returned to Bloemfontein to spearhead the expansion of patient studies in collaboration with the Faculty of Health Sciences.

“The opportunities we have here are really enormous,” says an excited Michelle.

“We are the only university in the country with this kind of infrastructure. Apart from our state-of-the-art bioanalytical lab, we also have facilities to accommodate close to 100 research participants. We now have 45 years’ experience in advanced medical research, plus established international clients. We can provide pharmaceutical companies with basically everything they need to develop new medicines.”

Another exciting development is that they are expanding their clinical-trial patient population next year from healthy individuals to people suffering from a host of chronic conditions.

“While they are part of our clinical trials, patients gain valuable insight in their own conditions. We also sometimes pick up underlying medical issues they were not even aware of,” says Michelle.

The 150 Farmovs staff members range from doctors and nurses, to technologists, medical writers, and managers. While not technically part of the university staff, they form a valued part of the Bloemfontein Campus community.

News Archive

UFS Doctors make History in South Africa
2011-07-14

 

New aortic valve

Three members of our Faculty of Health Sciences made history by being the first to implant a special new aortic valve in South Africa. 
 
In a combined effort, the Departments of Cardiology, Pediatric Cardiology and Cardiothoracic Surgery did the first Medtronic CoreValve implant in South Africa on a patient in Universitas Academic Hospital. 
 
With the support of hospital management and the Medtronic company, Prof. Hennie Theron, Prof. Stephen Brown and Dr JP Theron of the Faculty of Health Sciences, with the assistance of Dr Jean-Claude Laborde, performed the operation early on Wednesday morning, 06 July 2011.
 
The advantage of this new valve is that it can be implanted percutaneously through a catheter from the groin. This eliminates the need for invasive surgery.
 
The valve is made from porcine pericardium (tissue derived from pigs) and is mounted on an expandable stent, which is threaded along an artery, until it reaches its desired position. Prof. Theron says the valve is especially useful in older patients who suffer from aortic valve disease and pose a high surgical risk. Furthermore, the use of this valve greatly reduces hospitalisation time, in comparison to traditional surgery.
 
“One patient already received an implant this morning and we hope to finish 2 more today,” Prof. Brown said, emphasizing the swiftness and efficiency of the new valve implanting process.
 
“It is a complex procedure, but this service can in future be offered to all patients in the public and private sectors of the Free State. It is heartwarming that the academic complex can take the lead in this modern, high-tech therapy.”
 
For more information on the procedure, please contact Prof. Theron at 051 4053428.
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept